ZYN002 Transdermal Gel Cannabidiol (CBD)
Sponsors
Harmony Biosciences Management Inc.
Conditions
Fragile X Syndrome (FXS)Fragile X syndrome (FXS)
Phase 3
An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults with Fragile X Syndrome
RecruitingCTIS2023-508165-33-00
Start: 2024-07-26Target: 5Updated: 2025-10-10
A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents, and Young Adults with Fragile X Syndrome - RECONNECT
CompletedCTIS2024-513888-99-00
Start: 2023-06-08End: 2025-08-29Target: 7Updated: 2025-07-01